PATENT CLAIM ANALYSIS

Application Number: 15942587
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.

Claim (Index 35):
The molecule or the pharmaceutically acceptable salt of such molecule of  claim 34 , wherein the 5\u2032 cap z\u2033 covalently attached at the 5\u2032 terminus of the sense strand is 1,3-propanediol, mono(dihydrogen phosphate) i.e. C3; and\n wherein in the antisense strand the ribonucleotide at the 5\u2032 terminus is phosphorylated, represented by phos, and the C3-C3 non-nucleotide overhang at the 3\u2032 terminus is phosphorylated, represented by \u2014C3-C3-pi.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 91.0
- Lexical Diversity: 1.26316
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14421845', '14426513', '13700942', '15433400', '13521033']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8240784833365393
- 35 USC 102 Novelty (BERT): 0.5975468672973173
- Combined Prediction Score: 0.8014253217326172
- Mean Citation Score: 425.007888
- Max Citation Score: 516.79877
- Similarity Product: 475.0884065112674

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test